PAM
VYNE icon

Premier Asset Management’s VYNE Therapeutics VYNE Stock Holding History

Premier Asset Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,544
Closed -$289K – 207
2020
Q4 		$289K Buy
+2,544
New +$320K 0.06% 145

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Premier Asset Management's VYNE Position: Q1 2021 in Review

Premier Asset Management sold out of VYNE Therapeutics (VYNE) in Q1 2021, closing a stake of 2,544 shares — an estimated $289K sold.

Premier Asset Management first reported a position in VYNE in Q4 2020 and held it in 1 quarter. The position peaked at $289K in Q4 2020. 89 funds tracked by Wall St. Rank hold VYNE as of Q1 2021.

  • Premier Asset Management reported no remaining VYNE Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Premier Asset Management sold 2,544 VYNE Therapeutics shares in Q1 2021, an estimated $289K.
  • Premier Asset Management first reported a position in VYNE Therapeutics in Q4 2020 and held it in 1 quarter.
  • Premier Asset Management's VYNE Therapeutics position peaked at $289K in Q4 2020.
  • 89 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2021.

Based on Premier Asset Management's 13F filing for Q1 2021, filed 12 May 2021.